Pulmonary vein isolation (PVI) is very effective for rhythm control in patients with paroxysmal atrial fibrillation (AF), but less successful in patients with persistent AF. Adding posterior wall ablation (PWA) to PVI is among the most promising ablation strategies to improve arrhythmiafree outcome in patients with persistent AF. Patients with left atrial posterior wall scar may benefit most from adding PWA to PVI. With previous ablation technology, posterior wall isolation (PWI) was difficult to achieve and increased the risk of procedural complications. With pulsed-field ablation (PFA), a technology is now available which is both very effective and safe for complete ablation of the posterior wall. The aim of this trial therefore is to compare the efficacy and procedural safety of two ablation strategies for the treatment of persistent AF using PFA: PVI only versus PVI with added PWA. The endpoint of atrial arrhythmia recurrence within 12 months will be assessed by an implantable cardiac monitor (ICM) with remote monitoring capabilities.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
206
Pulmonary vein isolation with Pulsed field ablation without left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
Pulmonary vein isolation with Pulsed field ablation with left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
Cantonal Hospital Baden
Baden, Switzerland
University Hospital Basel
Basel, Switzerland
Inselspital, University Hospital Bern
Bern, Switzerland
University Hospital Lausanne
Lausanne, Switzerland
Cantonal Hospital St. Gallen
Sankt Gallen, Switzerland
University Hospital Zürich
Zurich, Switzerland
Time to first recurrence of any atrial tachyarrhythmia
Time to first recurrence of atrial tachyarrhythmia (atrial fibrillation \[AF\], atrial flutter \[AFL\] or atrial tachycardia \[AT\]) between days 91 and 365 post ablation as detected on an implantable cardiac monitor (ICM). AF, AFL or AT will qualify as a recurrence after ablation if it lasts 120 seconds or longer on the ICM (the minimum programmable episode interval)
Time frame: Days 91 to 365 post-ablation
Incidence of treatment-emergent adverse events: Cardiac tamponade
Number of patients with cardiac tamponade requiring drainage after PVI
Time frame: Days 0 to 90 post-ablation
Incidence of treatment-emergent adverse events: Persistent phrenic nerve palsy
Number of patients with persistent phrenic nerve palsy lasting \>24 hours after PVI
Time frame: Days 0 to 90 post-ablation
Incidence of treatment-emergent adverse events: Serious vascular complication
Number of patients with serious vascular complications requiring intervention after PVI
Time frame: Days 0 to 90 post-ablation
Incidence of treatment-emergent adverse events: Stroke or TIA
Number of patients with stroke or TIA after PVI
Time frame: Days 0 to 90 post-ablation
Incidence of treatment-emergent adverse events: Atrioesophageal fistula
Number of patients with atrioesophageal fistula after PVI
Time frame: Days 0 to 90 post-ablation
Incidence of treatment-emergent adverse events: Death
Number of patients with fatal outcome/death after PVI
Time frame: Days 0 to 90 post-ablation
Total procedure time
Procedural endpoint
Time frame: Day 0, during procedure
Total left atrial indwelling time
Procedural endpoint
Time frame: Day 0, during procedure
Total fluoroscopy time
Procedural endpoint
Time frame: Day 0, during procedure
Total radiation dose
Procedural endpoint
Time frame: Day 0, during procedure
Change in hs-Troponin on day 1 post-ablation
Procedural endpoint
Time frame: Day 1 post-ablation
Pre-ablation 3D electro-anatomical mapping: Number of participants with scar as a region that demonstrated reproducibly an area of > 0.5×0.5 cm on the posterior wall with voltage less than 0.5 mV
Procedural endpoint
Time frame: Day 0, shortly before ablation
Post-ablation 3D electro-anatomical mapping: Proportion of isolated veins
Procedural endpoint
Time frame: Day 0, shortly after ablation
Post-ablation 3D electro-anatomical mapping: Proportion of isolated carinas
Procedural endpoint
Time frame: Day 0, shortly after ablation
Post-ablation 3D electro-anatomical mapping: Lesion size
Procedural endpoint
Time frame: Day 0, shortly after ablation
Post-ablation 3D electro-anatomical mapping: Posterior wall ablation success rate
Procedural endpoint
Time frame: Day 0, shortly after ablation
Time to first recurrence of any atrial tachyarrhythmia in patients with versus without left atrial posterior wall scar
Secondary endpoint during follow-up
Time frame: Day 0 to 36 months post-ablation
Time to first recurrence of any atrial tachyarrhythmia in patients with left atrial posterior wall scar and posterior wall ablation versus without posterior wall ablation
Secondary endpoint during follow-up
Time frame: Day 0 to 36 months post-ablation
Percentage of time with cardiac arrhythmia (arrhythmia burden) for each participant between days 0-90 evaluated based on continuous ICM
Secondary endpoint during follow-up
Time frame: Day 0 to 90 post-ablation
Percentage of time with cardiac arrhythmia (arrhythmia burden) for each participant between days 91-365 evaluated based on continuous ICM
Secondary endpoint during follow-up
Time frame: Day 91 to 365 post-ablation
Percentage of time with cardiac arrhythmia (arrhythmia burden) for each participant between days 365 until explantation or end of life (EOL) of the ICM
Secondary endpoint during follow-up
Time frame: Day 365 post-ablation to explantation of ICM or end of life of ICM (up to 4 years after implantation of ICM)
Correlation of AF burden to symptoms and quality of life changes
Secondary endpoint during follow-up; Quality of life wil be measured with the EQ-5D-5L questionnaire where higher scores mean better outcomes; Symptoms will be measured with the AFEQT (Atrial Fibrillation Effect on Quality-of-life) questionnaire where higher scores mean worse outcomes
Time frame: Day 0 and months 3 and 12 post-ablation
Reduction of percentage of time with cardiac arrhythmia (AF burden) by > 90% post ablation procedure
Secondary endpoint during follow-up
Time frame: Day 0 to 36 months post-ablation
Comparison of the prevalence of the type of arrhythmia recurrence during follow-up being AF or organized atrial arrhythmias (AFL or AT)
Secondary endpoint during follow-up
Time frame: Day 0 to 36 months post-ablation
Time to first recurrence of atrial tachyarrhythmia between days 91 and 365 evaluated based on continuous ICM in patients with presence of scar on the PW based on the preablation voltage map versus patients with no scar on the PW
Secondary endpoint during follow-up
Time frame: Day 91 to 365 post-ablation
Number of participants with persistent or paroxysmal AF during follow-up
Secondary endpoint during follow-up
Time frame: Day 0 to 36 months post-ablation
Average heart rate as recorded by the ICM in months 1, 2 and 3 after ablation
Secondary endpoint during follow-up
Time frame: Months 1, 2 and 3 after ablation
Proportion of patients admitted to the hospital or emergency room because of documented recurrence of atrial arrhythmias
Secondary endpoint during follow-up
Time frame: Day 0 to 36 months post-ablation
Proportion of patients undergoing a repeat ablation procedure because of documented recurrence of atrial arrhythmias
Secondary endpoint during follow-up
Time frame: Day 0 to 36 months post-ablation
Number of participants reinitiating of antiarrhythmic drugs during follow-up
Secondary endpoint during follow-up
Time frame: Day 0 to 36 months post-ablation
Number of participants with electrical cardioversion during follow-up
Secondary endpoint during follow-up
Time frame: Day 0 to 36 months post-ablation
Number of reconnected pulmonary veins evaluated during redo procedures
Secondary endpoint during follow-up
Time frame: During redo procedures between day 1 to 36 months post-ablation
Sites of reconnection (anterior, posterior, superior, inferior) of the pulmonary veins evaluated during redo procedures
Secondary endpoint during follow-up
Time frame: During redo procedures between day 1 to 36 months post-ablation
Size of antral scar area (cm²) of the pulmonary veins evaluated during redo procedures
Secondary endpoint during follow-up
Time frame: During redo procedures between day 1 to 36 months post-ablation
Number of reconnected posterior walls evaluated during redo procedures
Secondary endpoint during follow-up
Time frame: During redo procedures between day 1 to 36 months post-ablation
Sites of reconnection of the posterior wall evaluated during redo procedures
Secondary endpoint during follow-up
Time frame: During redo procedures between day 1 to 36 months post-ablation
Size of the scar area (cm²) of the posterior wall evaluated during redo procedures
Secondary endpoint during follow-up
Time frame: During redo procedures between day 1 to 36 months post-ablation
Evolution of Quality of Life after 3 and 12 months
Secondary endpoint during follow-up; Quality of life wil be measured with the EQ-5D-5L questionnaire where higher scores mean better outcomes
Time frame: Day 0 and months 3 and 12 post-ablation
Number of participants with stroke including TIA after 3, 12, 24 and 36 months
Secondary endpoint during follow-up
Time frame: Months 3, 12, 24 and 36 post-ablation
Number of participants with cardiovascular or non-cardiovascular death after 3, 12, 24 and 36 months
Secondary endpoint during follow-up
Time frame: Months 3, 12, 24 and 36 post-ablation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.